Looking forward, this approach can be extended to experimental validation, structure–activity optimization, and clinical translation, offering a scalable pathway for developing next-generation therapeutics targeting JAK3-driven cancers and immune disorders. This evidence concerns the gene JAK3 and immune system disorder.